scholarly journals Synthesis of Zwitter-Ionic Conjugate of Nido-Carborane with Cholesterol

Molecules ◽  
2021 ◽  
Vol 26 (21) ◽  
pp. 6687
Author(s):  
Anna A. Druzina ◽  
Olga B. Zhidkova ◽  
Nadezhda V. Dudarova ◽  
Natalia A. Nekrasova ◽  
Kyrill Yu. Suponitsky ◽  
...  
Keyword(s):  
Molecular Structure ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Terminal Alkyne ◽  
X Ray Diffraction ◽  
Dimethylamino Group ◽  
X Ray ◽  
Boron Neutron Capture ◽  
Carborane Derivative ◽  
A Charge

9-HC≡CCH2Me2N-nido-7,8-C2B9H11, a previously described carboranyl terminal alkyne, was used for the copper(I)-catalyzed azide-alkyne cycloaddition with azido-3β-cholesterol to form a novel zwitter-ionic conjugate of nido-carborane with cholesterol, bearing a 1,2,3-triazol fragment. The conjugate of nido-carborane with cholesterol, containing a charge-compensated group in the linker, can be used as a precursor for the preparation of liposomes for BNCT (Boron Neutron Capture Therapy). The solid-state molecular structure of a nido-carborane derivative with the 9-Me2N(CH2)2Me2N-nido-7,8-C2B9H11 terminal dimethylamino group was determined by single-crystal X-ray diffraction.

scholarly journals Synthesis and Structure of Nido-Carboranyl Azide and Its “Click” Reactions

Molecules ◽  
2021 ◽  
Vol 26 (3) ◽  
pp. 530
Author(s):  
Anna A. Druzina ◽  
Olga B. Zhidkova ◽  
Nadezhda V. Dudarova ◽  
Irina D. Kosenko ◽  
Ivan V. Ananyev ◽  
...  
Keyword(s):  
Molecular Structure ◽  
Neutron Capture ◽  
Cluster Compounds ◽  
Neutron Capture Therapy ◽  
Terminal Alkynes ◽  
X Ray Diffraction ◽  
Click Reactions ◽  
X Ray ◽  
Boron Neutron Capture ◽  
Cobalt Iron

Novel zwitter-ionic nido-carboranyl azide 9-N3(CH2)3Me2N-nido-7,8-C2B9H11 was prepared by the reaction of 9-Cl(CH2)3Me2N-nido-7,8-C2B9H11 with NaN3. The solid-state molecular structure of nido-carboranyl azide was determined by single-crystal X-ray diffraction. 9-N3(CH2)3Me2N-nido-7,8-C2B9H11 was used for the copper(I)-catalyzed azide-alkyne cycloaddition with phenylacetylene, alkynyl-3β-cholesterol and cobalt/iron bis(dicarbollide) terminal alkynes to form the target 1,2,3-triazoles. The nido-carborane-cholesterol conjugate 9-3β-Chol-O(CH2)C-CH-N3(CH2)3Me2N-nido-7,8-C2B9H11 with charge-compensated group in a linker can be used as a precursor for preparation of liposomes for Boron Neutron Capture Therapy (BNCT). A series of novel zwitter-ionic boron-enriched cluster compounds bearing a 1,2,3-triazol-metallacarborane-carborane conjugated system was synthesized. Prepared conjugates contain a large amount of boron atom in the biomolecule and potentially can be used for BNCT.

The status of Tsukuba BNCT trial: BPA-based boron neutron capture therapy combined with X-ray irradiation

2011 ◽  
Vol 69 (12) ◽  
pp. 1817-1818 ◽  
Author(s):  
T. Yamamoto ◽  
K. Nakai ◽  
T. Nariai ◽  
H. Kumada ◽  
T. Okumura ◽  
...  
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
X Ray ◽  
Boron Neutron Capture ◽  
The Status

scholarly journals Carborane derivative development for boron neutron capture therapy. Final report

1999 ◽  
Author(s):  
Beverly A. Barnum ◽  
Yan Hao ◽  
Roger Moore ◽  
M. Frederick Hawthorne ◽  
Kurt Baum
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Final Report ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture ◽  
Carborane Derivative

Accelerator-driven boron neutron capture therapy

2014 ◽  
Vol 29 (14) ◽  
pp. 1441004 ◽  
Author(s):  
Rob Edgecock
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
State Of The Art ◽  
Technical Problem ◽  
Hospital Environment ◽  
Neutron Capture Therapy ◽  
X Ray ◽  
Boron Neutron Capture ◽  
Uptake Process ◽  
Cancerous Cells

Boron Neutron Capture Therapy is a binary treatment for certain types of cancer. It works by loading the cancerous cells with a boron-10 carrying compound. This isotope has a large cross-section for thermal neutrons, the reaction producing a lithium nucleus and alpha particle that kill the cell in which they are produced. Recent studies of the boron carrier compound indicate that the uptake process works best in particularly aggressive cancers. Most studied is glioblastoma multiforme and a trial using a combination of BNCT and X-ray radiotherapy has shown an increase of nearly a factor of two in mean survival over the state of the art. However, the main technical problem with BNCT remains producing a sufficient flux of neutrons for a reasonable treatment duration in a hospital environment. This paper discusses this issue.

scholarly journals Fe3O4 Nanoparticles for Complex Targeted Delivery and Boron Neutron Capture Therapy

Nanomaterials ◽  
2019 ◽  
Vol 9 (4) ◽  
pp. 494 ◽  
Author(s):  
Kanat Dukenbayev ◽  
Ilya Korolkov ◽  
Daria Tishkevich ◽  
Artem Kozlovskiy ◽  
Sergey Trukhanov ◽  
...  
Keyword(s):  
Mössbauer Spectroscopy ◽  
Boron Neutron Capture Therapy ◽  
Fe3o4 Nanoparticles ◽  
Neutron Capture ◽  
Mossbauer Spectroscopy ◽  
Neutron Capture Therapy ◽  
X Ray ◽  
Mößbauer Spectroscopy ◽  
Boron Neutron Capture ◽  
Fe3o4 Nps

Magnetic Fe3O4 nanoparticles (NPs) and their surface modification with therapeutic substances are of great interest, especially drug delivery for cancer therapy, including boron-neutron capture therapy (BNCT). In this paper, we present the results of boron-rich compound (carborane borate) attachment to previously aminated by (3-aminopropyl)-trimethoxysilane (APTMS) iron oxide NPs. Fourier transform infrared spectroscopy with Attenuated total reflectance accessory (ATR-FTIR) and energy-dispersive X-ray analysis confirmed the change of the element content of NPs after modification and formation of new bonds between Fe3O4 NPs and the attached molecules. Transmission (TEM) and scanning electron microscopy (SEM) showed Fe3O4 NPs’ average size of 18.9 nm. Phase parameters were studied by powder X-ray diffraction (XRD), and the magnetic behavior of Fe3O4 NPs was elucidated by Mössbauer spectroscopy. The colloidal and chemical stability of NPs was studied using simulated body fluid (phosphate buffer—PBS). Modified NPs have shown excellent stability in PBS (pH = 7.4), characterized by XRD, Mössbauer spectroscopy, and dynamic light scattering (DLS). Biocompatibility was evaluated in-vitro using cultured mouse embryonic fibroblasts (MEFs). The results show us an increasing of IC50 from 0.110 mg/mL for Fe3O4 NPs to 0.405 mg/mL for Fe3O4-Carborane NPs. The obtained data confirm the biocompatibility and stability of synthesized NPs and the potential to use them in BNCT.

scholarly journals “Free of Base” Sulfa-Michael Addition for Novel o-Carboranyl-DL-Cysteine Synthesis

Crystals ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 1133
Author(s):  
Julia Laskova ◽  
Irina Kosenko ◽  
Ivan Ananyev ◽  
Marina Stogniy ◽  
Igor Sivaev ◽  
...  
Keyword(s):  
Michael Addition ◽  
Addition Reaction ◽  
Neutron Capture Therapy ◽  
Michael Addition Reaction ◽  
X Ray Diffraction ◽  
Deuterium Label ◽  
X Ray ◽  
Boron Neutron Capture ◽  
Cysteine Synthesis ◽  
Base Method

The sulfa-Michael addition reaction was applied for the two-step synthesis of o-carboranyl cysteine 1-HOOCCH(NH2)CH2S-1,2-C2B10H11 from the trimethylammonium salt of 1-mercapto-o-carborane and methyl 2-acetamidoacrylate. To avoid the decapitation of o-carborane into its nido-form, the “free of base” method under mild conditions in a system of two immiscible solvents toluene-H2O was developed. The replacement of H2O by 2H2O resulted in carboranyl-cysteine containing a deuterium label at the α-position of the amino acid 1-HOOCCD(NH2)CH2S-1,2-C2B10H11. The structure of the protected o-carboranyl cysteine was determined by single-crystal X-ray diffraction. The obtained compounds can be considered as potential agents for the Boron Neutron Capture Therapy of cancer.

Sign in / Sign up

Export Citation Format

Share Document